Pathophysiology of airflow limitation in chronic obstructive pulmonary disease.

By J. Hogg. The Lancet, 2004

1,300 citations recorded by the source corpus.

Subfields: Physiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/2d0d3f98ac46cac09d0325c7fbf40c89f5261616

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. (2007, background): “Chronic inflammatory changes with increased numbers of inflammatory cell types, and structural changes resulting from repeated injury and repair, are found in the airways, lung parenchyma, and pulmonary vasculature of patients with COPD (35).”
Immunology of asthma and chronic obstructive pulmonary disease (2008, background): “In biopsies of the bronchial airways, small airways and lung parenchyma from patients with COPD, there is no evidence for mast-cell activation, but there is an infiltration of T cells and increased numbers of neutrophils, particularly in the airway lume”
Pathogenesis of chronic obstructive pulmonary disease. (2005, background): “In chronic bronchitis there is inflammation in the epithelium of the central airways and in the mucus-producing glands (3).”
Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. (2007, background): “For instance, inflammation is associated with atherosclerosis (2, 3), diabetes (4), obesity (5), smoking-related illnesses (6), dementia (7), osteoporosis (8), and macular degeneration (9).”
Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution (2023, neutral): “периферических дыхательных путях, паренхиме легких и легочных сосудах [86].”